CRP and hepatocellular carcinoma: These promoter constructs were transfected into the Alexander human hepatoma cells which were then treated as shown in Fig. 4C. The wild-type promoter behaved as expected based on results shown in Fig. 3, that is, gemcabene alone had no effect on CRP expression, induction occurred following IL-6 treatment, which was inhibited by gemcabene pretreatment.